Eiger BioPharmaceuticals Overview
Eiger BioPharmaceuticals (EIGR) has a ROE of 518.49%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow518.49%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, EIGR shows a ROE of 518.49%. That is above the Healthcare sector average of 21.67%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.67%. Eiger BioPharmaceuticals is at 518.49%, which is higher that average. That is roughly 2292.9% above the sector mean. Use the comparison chart on this page to see how EIGR stacks up against individual peers as well.
Check the historical chart to see whether EIGR's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Eiger BioPharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Eiger BioPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 518.49%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.67%, while EIGR is at 518.49%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
